Prescribing the antibiotic clarithromycin for patients with stable coronary heart disease could increase their risk of dying of cardiovascular disease or developing cerebrovascular disease, the FDA has warned.
The agency’s recent drug safety communication is based on 10 years of follow-up from a trial involving 4372 patients with stable coronary heart disease. For 2 weeks, half received a placebo and half received 500 mg per day of clarithromycin. Overall, the drug conferred a 10% increased risk of death from any cause and a 19% increased risk of developing cerebrovascular disease.
Voelker R. Another Caution for Clarithromycin. JAMA. 2018;319(13):1314. doi:10.1001/jama.2018.2945
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: